Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A U.S. retrospective database analysis evaluating the comparative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol among asthma patients
Age
12–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Continuous health plan enrollment for 12 months before and after index Rx
At least two prescription fills for BFC or FSC within 12 months
Asthma claims diagnosis, and 12 to 64 years of age at the time of first prescription
You may not be if
Evidence of COPD
Claims diagnosis of any of inflammatory diseases or cancer
Presence of Rx for more than one type of ICS/LABA combination on index date
Chronic steroid use or Xolair use prior to ICS/LABA index treatment
Clareo Health | Asthma Comparative Effectiveness Study
